Lambda Biologics GmbH is pleased to announce its participation as a member of the organizing committee for the Organoid Developer Conference (ODC) 2025. This global event will take place from June 13–14, 2025 at Magok COEX in Seoul, South Korea, and will bring together leaders in organoid research, regenerative medicine, non-animal testing, bioart, and future technologies.
Organized under the theme “New Beginnings: A Festival of Science, Art & Culture”, ODC 2025 aims to create a multidisciplinary platform where science, technology, and creative expression converge. The conference will feature groundbreaking sessions that highlight emerging trends and transformative approaches across the life sciences.
As a biotechnology company committed to advancing organoid-based research and innovative non-animal testing solutions, Lambda Biologics is honored to contribute to shaping the direction of this important international forum.
ODC 2025 serves as a global collaborative platform for over 2,000 participants, including researchers, artists, industry leaders, and policymakers. The conference promotes interdisciplinary dialogue and innovation by bridging scientific advancements with cultural and societal perspectives.
Featured Sessions at ODC 2025:
- Organoid and Artificial Organ Research: Emerging technologies driving the future of regenerative medicine
- Organoid Intelligence (OI): Integrating biological computing and next-generation AI
- Precision Medicine: Current developments and future directions in personalized therapeutics
- Sustainable Technology: Future-oriented solutions for sustainable life science innovations
- Food Technology: Advancements in alternative proteins and next-generation food systems
- AFI Global Idea Challenge: A competitive showcase of breakthrough ideas from early-stage researchers and startups
- Science Art & Fashion Technology: Cross-disciplinary experiences where science inspires creative expression
Advancing Organoid Science and Ethical Innovation
Lambda Biologics’ role in ODC 2025 aligns with the company’s broader mission to support the development and application of organoid-based platforms in areas such as cancer research, regenerative medicine, and non-animal testing methodologies. The company believes in dissolving boundaries between disciplines to foster innovation and accelerate scientific impact.
Participation in this global event enables Lambda Biologics to contribute to the future of organoid research and ethical biomedical innovation, while actively engaging with a diverse community of stakeholders across science, art, and industry.
Lambda Biologics looks forward to supporting the success of ODC 2025 and contributing to meaningful conversations around organoid innovation, non-animal testing, and the future of biomedical science. Stay connected with us as we continue to collaborate, inspire, and shape the future of healthcare.
